Immune-Modifying Framework

By RRM Academy Reviewed by Dr. Naomi Whittaker, MD, Board-Certified OBGYN, MIGS, NFPMC, FCI Updated May 14, 2026

The Immune-Modifying Framework is a clinical orientation adopted in some restorative reproductive medicine practices for couples experiencing recurrent pregnancy loss or unexplained implantation failure, in which immune system contributors are evaluated and addressed as part of the diagnostic workup. The framework is most explicitly developed within NeoFertility's clinical approach under Dr. Phil Boyle, though related immunological evaluation appears across multiple named-method practices. The core premise is that dysregulated immune activity at the implantation interface can be a diagnosable contributor to pregnancy failure, rather than an idiopathic outcome.¹²

Immune contributors that may be investigated include antiphospholipid syndrome, uterine natural killer cell activity, autoimmune thyroid disease, inherited or acquired thrombophilia, and chronic endometritis.³⁴⁵ These are not investigated as a fixed panel applied uniformly. The framework is inherently individualized: which investigations a clinician pursues depends on the couple's clinical history, prior pregnancy outcomes, and the specific named method guiding that practice.¹ Investigation and treatment within this framework require direct physician oversight; the approach cannot be standardized across all restorative practices.

The immune-modifying orientation reflects a broader principle in restorative care: that recurrent pregnancy loss and implantation failure deserve diagnostic investigation rather than empiric bypass.³ ART protocols address implantation failure by optimizing the embryo transfer environment or adding cycles; the immune-modifying framework asks instead whether a correctable physiological condition is present. This contrast is central to the corrective-vs-bypass distinction. and autoimmune-thrombophilic conditions.

The framework remains an active area of clinical investigation. Evidence standards for specific interventions vary considerably across the immune contributors involved. NeoFertility has published outcomes data on couples with implantation failure and recurrent loss,⁶ and the OPTIMUM treatment strategy developed in Japan addresses overlapping immune and thrombotic contributors in a structured multi-modal protocol.⁷ Couples with documented immune contributors benefit most from evaluation by a clinician trained in a named method that formally incorporates this framework.

This content is for educational purposes only and does not constitute medical advice. Consult an RRM clinician or healthcare provider for guidance specific to your situation.